Business Context and Reporting Period
This Form 6-K filing by Dr. Reddy's Laboratories Limited covers the month of June 2004. The registrant is an emerging global pharmaceutical company incorporated in India, with operations spanning finished dosage forms, active pharmaceutical ingredients, and biotechnology products. The filing primarily discloses corporate governance updates and regulatory approvals rather than financial results.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity for the period. No financial statements or quantitative performance metrics are included in this specific report.
Material Changes and Corporate Events
- Regulatory Approval: On June 10, 2004, the USFDA granted final approval for the Company's Abbreviated New Drug Application (ANDA) for Ciprofloxacin tablets in strengths of 100 mg, 250 mg, 500 mg, and 750 mg.
- Market Exclusivity: The company is eligible for 180 days of market exclusivity specifically for the 100 mg strength of Ciprofloxacin.
- Product Context: Ciprofloxacin is the AB-rated generic equivalent of Bayer Corporation's Cipro. The brand product had estimated annual US sales of approximately US $1 billion in 2003.
- Change in Cost Auditors: On June 4, 2004, the company announced that M/s. R R Sharma & Co. would not seek re-appointment for the 2004-05 financial year. The Board appointed M/s Sagar & Associates as the new Cost Auditors, subject to Central Government approval.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer regarding forward-looking statements. Management notes that actual results may differ materially due to risks including changes in economic conditions, strategy implementation, market acceptance of products, technological changes, and market risks. No specific financial guidance or outlook figures were provided in this document.
Investor Verification Checklist
- Verify the commercial launch timeline for the newly approved Ciprofloxacin tablets.
- Confirm the final approval status of M/s Sagar & Associates by the Central Government.
- Monitor the impact of the 180-day market exclusivity on revenue generation for the 100 mg strength.
- Review subsequent filings for the next quarterly or annual financial results, as none are present here.